Breaking News

Be wary of private equity's entrance into urgent care

Not rendering correctly? View this email as a web page here.
SPONSORED

AstraZeneca & Daiichi drug wins another FDA approval, this time in lung cancer

By Frank Vinluan Sunday, August 14, 2022 10:21 AM

On the heels of receiving a landmark FDA approval in breast cancer, AstraZeneca and Daiichi Sankyo drug Enhertu won an additional approval in non-small cell lung cancer. The decision makes the drug the first targeted NSCLC therapy addressing the cancer protein HER2.

Read more »

   

No comments